X-linked sideroblastic anemia

What it is, symptoms and effects

From: MedlinePlus Genetics, National Library of Medicine

X-linked sideroblastic anemia belongs to a group of disorders that are characterized by a shortage of healthy red blood cells (anemia). X-linked sideroblastic anemia prevents developing red blood cells from making enough hemoglobin, which is the protein that carries oxygen in the blood. People with X-linked sideroblastic anemia have red blood cells that are smaller than normal (microcytic) and appear pale (hypochromic) because of the shortage of hemoglobin. This disorder also leads to an abnormal accumulation of iron in red blood cells. The iron-loaded red blood cells, which are present in bone marrow, are called ring sideroblasts.

The signs and symptoms of X-linked sideroblastic anemia are caused by a combination of too little hemoglobin and too much iron. Common signs and symptoms include extreme tiredness (fatigue), dizziness, a rapid heartbeat, pale skin, and an enlarged liver and spleen (hepatosplenomegaly). Over time, severe health problems such as heart disease and liver damage (cirrhosis), can result from the buildup of iron in these organs.

Males with X-linked sideroblastic anemia typically have the classic signs and symptoms of the condition, while females tend to be less severely affected. Females with X-linked sideroblastic anemia usually develop features of the condition in mid to late adulthood, while affected males often first experience symptoms in adolescence to early adulthood.

ORPHANET DEFINITION X-linked sideroblastic anemia is a constitutional microcytic, hypochromic anemia of varying severity that is clinically characterized by manifestations of anemia and iron overload and that may respond to treatment with pyridoxine and folic acid.

Causes

From: MedlinePlus Genetics, National Library of Medicine

The signs and symptoms of X-linked sideroblastic anemia are caused by a combination of too little hemoglobin and too much iron. Over time, severe health problems such as heart disease and liver damage (cirrhosis), can result from the buildup of iron in these organs.

Frequency in the source

From: MedlinePlus Genetics, National Library of Medicine

Reported case(s): 200.0; Worldwide. This is a published case count, not prevalence. Point prevalence: Unknown; Worldwide; Class only.

Reported clinical features and what the terms mean

The following findings are associated with this condition in Orphanet. They are not a checklist for diagnosing yourself, and they do not all occur in every affected person. Some are examination, imaging or laboratory findings that cannot be recognised at home.

The frequency labels describe how often a finding was reported among people with the condition in the source. They do not give the chance that a person with that symptom has the condition. Definitions below reproduce HPO terminology; they explain the term, not the likely severity in an individual.

Abnormality of iron homeostasis · Very frequent (99-80%)

An abnormality of the homeostasis (concentration) of iron cation.

Anemia · Very frequent (99-80%)

A reduction in erythrocytes volume or hemoglobin concentration.

Fatigue · Very frequent (99-80%)

A subjective feeling of tiredness characterized by a lack of energy and motivation.

Muscle weakness · Very frequent (99-80%)

Reduced strength of muscles.

Pallor · Very frequent (99-80%)

Abnormally pale skin.

Dyspnea · Occasional (29-5%)

Difficult or labored breathing. Dyspnea is a subjective feeling only the patient can rate, e.g., on a Borg scale.

Elevated circulating hepatic transaminase concentration · Occasional (29-5%)

Elevations of the levels of SGOT and SGPT in the serum. SGOT (serum glutamic oxaloacetic transaminase) and SGPT (serum glutamic pyruvic transaminase) are transaminases primarily found in the liver and heart and are released into the bloodstream as the result of liver or heart damage. SGOT and SGPT are used clinically mainly as markers of liver damage.

Glucose intolerance · Occasional (29-5%)

Glucose intolerance (GI) can be defined as dysglycemia that comprises both prediabetes and diabetes. It includes the conditions of impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) and diabetes mellitus (DM).

Hyperpigmentation of the skin · Occasional (29-5%)

A darkening of the skin related to an increase in melanin production and deposition.

Splenomegaly · Occasional (29-5%)

Abnormal increased size of the spleen.

When it may begin

From: MedlinePlus Genetics, National Library of Medicine

All ages

Inheritance in the source

From: MedlinePlus Genetics, National Library of Medicine

X-linked

Frequency and the population described

From: MedlinePlus Genetics, National Library of Medicine

Reported case(s): 200.0; Worldwide. This is a published case count, not prevalence. Point prevalence: Unknown; Worldwide; Class only.

Which doctor should you see?

The suggested department for discussing X-linked sideroblastic anemia is Haematology, with a haematologist as the relevant type of clinician. General physician / Family Medicine; paediatrician for children. Referral depends on symptoms.

Additional services that may be relevant, depending on the findings, include: Clinical Genetics.

This is an editorial referral starting point. The appropriate clinic depends on the person’s age, symptoms, previous diagnosis and local services. The first clinician can decide whether another specialty or a team is needed; a department label does not confirm the diagnosis.

How to prepare for an assessment

Bring a short timeline of the main symptoms: when they first appeared, whether they are constant or episodic, what seems to change them, and how they affect daily activities. Include previous reports, discharge summaries, current medicines and supplements, allergies, and any relevant family history. A dated record is more useful than trying to match every feature in an online article.

Ask the clinician what is already established and what remains uncertain. If a test is suggested, ask what question it answers, what its limitations are and how the result would change the next step. The information here is not an instruction to arrange every possible test. In children, bring growth, developmental and school information if it is relevant to the concern.

• Which blood-cell, marrow, bleeding or clotting finding matters most?
• Does the diagnosis need confirmation or a more precise subtype?
• Which symptoms or laboratory changes should trigger earlier review?

Treatment discussions and follow-up

The material gathered for this draft does not provide a complete condition-specific treatment pathway for X-linked sideroblastic anemia. That gap does not mean that treatment is unavailable. A clinician needs to establish the diagnosis and review current guidance before recommending medicines, procedures, rehabilitation or other support.

Before leaving the appointment, clarify the next review date, who will communicate results, and whom to contact if the situation changes. Discuss difficulties with sleep, work, school, mobility, eating or emotional wellbeing when these are relevant. Practical support may require coordination between the treating clinician and other services.

The collected references do not establish a complete prevention or long-term outlook section for this entry. Missing information should not be interpreted as proof that prevention is impossible or that a particular outcome is inevitable. Ask what is known for the exact subtype, stage and personal circumstances, and which uncertainties remain.

When to seek emergency help

Severe breathing difficulty, collapse, new stroke-like symptoms, a seizure that is prolonged or repeated without recovery, uncontrolled major bleeding, or an immediate risk of self-harm require emergency help. In India, call 112 or reach the nearest emergency department. This is a general, non-exhaustive warning list; it is not a condition-specific triage tool.